Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial o...(cebo. Trial results are expected in the ...),Health

About Orexigen Therapeutics

Orexigen(R) Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's late-stage product candidates targeting obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM), which is in Phase IIb clinical development. Orexigen is developing other proprietary drugs for use in other central nervous system disorders. Further information about the Company and its pipeline can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the efficacy and safety of the various formulations of Empatic, the potential to obtain regulatory approval for, and effectively treat obesity with, Empatic and Contrave and the enrollment, timing and completion of clinical trials of Contrave and Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Company's business, including, without limitation: the progress and timing of the Company's clinical trials; the potential that earlier clinical trials may not be predictive of future results; the ability for Empatic
'/>"/>